Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 13/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897327 | 0.77 | MAP4K4 (0.62) | PI4K2AMAP4K4EGFR | |
| SCHEMBL29663392 | 0.76 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL6096033 | 0.76 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL27758587 | 0.75 | ADORA2A (0.57) | MAP4K4EGFR | |
| SCHEMBL12545778 | 0.74 | MAP4K4 (0.49) | PI4K2AMAP4K4EGFR | |
| SCHEMBL10971103 | 0.74 | MAP4K4 (0.65) | PI4K2AMAP4K4EGFR | |
| SCHEMBL6442231 | 0.73 | NR4A2 (0.56) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL7376295 | 0.73 | MAP4K4 (0.54) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL16755291 | 0.73 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL4431055 | 0.73 | MAP4K4 (0.54) | PI4KAPI4K2BPI4K2API4KBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | claimed |
| US-9737509-B1 | Antimicrobial compositions, methods of use, and methods of treatment of infections | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2016191412-A1 | ANTIMICROBIAL COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT OF INFECTIONS | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-12-01 | — | — | WO | disclosed |
| US-7678803-B2 | Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones | SERENEX, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678803-B2 | Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones | SERENEX, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678803-B2 | Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones | SERENEX, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | PI4KA 2665/4885PI4K2B 3000/4885PI4K2A 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.